November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Ramzi Khamis: Higher Levels of Natural Antibodies Against Malondialdehyde-Modified LDL
Nov 7, 2025, 03:26

Ramzi Khamis: Higher Levels of Natural Antibodies Against Malondialdehyde-Modified LDL

Ramzi Khamis, The Wu Family Endowed Chair of Cardiology at the National Heart and Lung Institute, posted on LinkedIn:

“Delighted to share our new publication.

This study extends the paradigm that immune responses to oxidised lipoproteins influence not only atherosclerosis, but also the biology of valvular calcification. Higher levels of natural antibodies against malondialdehyde-modified LDL (MDA-LDL), particularly IgM, were associated with less aortic and mitral valve calcification on CT imaging.

These findings lend further weight to the concept that the immune system’s recognition of oxidised lipid epitopes may confer a degree of vascular protection , an area that continues to bridge vascular immunology, lipid oxidation, and imaging science.

Congratulations to Adam Hartley and the team. We are so greatful to the outstanding SCOT-HEART team, whose meticulous imaging phenotyping and translational curiosity made this work possible. A wonderful example of how population imaging and molecular immunology can converge to illuminate new dimensions of cardiovascular disease. Kudos to Michelle Williams, David Newby and the team who made this possible.”

Title: Anti‐Malondialdehyde Low‐Density Lipoprotein Antibodies and Valvular Calcification: A Substudy of the SCOT‐HEART Trial

Authors: Adam Hartley, Michelle C. Williams, Amit Kaura, Sarah Verhemel, Mikhail Caga-Anan, Damini Dey, Marc R. Dweck, Dorian O. Haskard, Michael Joner, Manuel Mayr, David E. Newby, Ramzi Y. Khamis

Ramzi Khamis: Higher Levels of Natural Antibodies Against Malondialdehyde-Modified LDL

Read full paper here.

Stay informed with Hemostasis Today.